Clinical trials - Press Releases

Date	Title	Company
10-Jan-2023	Positive Initial Data Analysis in POLB 001 LPS Challenge Trial	Poolbeg Pharma Plc
06-Jan-2023	Egnyte to provide early-stage life science startups a year of Egnyte’s platform at no cost	Egnyte
06-Jan-2023	atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression	atai Life Sciences
06-Jan-2023	Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration	Transgene
06-Jan-2023	HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations	HighTide Therapeutics Inc.
05-Jan-2023	Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer	Nouscom
05-Jan-2023	Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders	Sosei Heptares
05-Jan-2023	STEMart Introduces API Impurity Identification Services for Medical Devices	STEMart
04-Jan-2023	ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma	ISA Pharmaceuticals
03-Jan-2023	Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions	Alphalyse
03-Jan-2023	HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China	HUTCHMED
22-Dec-2022	Hataali and Reef Group announce strategic partnership for ATMP Smart Labs	Hataali
22-Dec-2022	OSE Immunotherapeutics Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in a Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas	OSE Immunotherapeutics
22-Dec-2022	Kancera submits regulatory application to conduct clinical study in ovarian cancer and enters into collaboration with the Nordic Society of Gynaecological Oncology	Kancera
21-Dec-2022	Innovative Antibody Discovered by RQ Bio Enters Clinic as Part of Antibody Combination Within 12 Months of Discovery	RQ Bio
20-Dec-2022	Clinical trial platform provider encapsia welcomes new COO	encapsia
20-Dec-2022	Novotech is Gold Sponsor at Biotech Showcase 2023	Novotech Health Holdings Pte Ltd
16-Dec-2022	Calypso Biotech Announces First Patient with Eosinophilic Esophagitis Dosed in Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 Phase 1a/b Trial, and Animal Proof of Concept Data in Atopic Dermatitis	Calypso Biotech
16-Dec-2022	Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study	Tiziana Life Sciences
15-Dec-2022	CellProthera expands clinical trial sites for phase IIb myocardial infarction study	CellProthera